AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt

Serina Therapeutics, Inc.

Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).
Cash and equivalents $0.3M at Dec 31, 2023; $4.5M owed to Juvenescence under line of credit.
Operating expenses rose to $10.1M from $7.0M, mainly due to merger due diligence and legal fees.
AgeX expresses substantial doubt about going concern; cash insufficient for next 12 months.
Stockholders approved merger with Serina Therapeutics; line of credit increased $4.4M, repayment extended to May 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Serina Therapeutics, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.

Period: fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 22, 2024, AgeX issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.